In the BioHarmony Drug Report Database
Rasagiline
Azilect, Rasagiline ratiopharm (rasagiline) is a small molecule pharmaceutical. Rasagiline was first approved as Azilect on 2005-02-21. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against amine oxidase [flavin-containing] B. In addition, it is known to target hypothetical protein. Azilect’s patents are valid until 2027-08-27 (FDA).
Trade Name
|
Azilect, Rasagiline ratiopharm |
|---|---|
Common Name
|
rasagiline |
ChEMBL ID
|
CHEMBL887 |
Indication
|
parkinson disease |
Drug Class
|
Mao inhibitors, type B |
Image (chem structure or protein)